Additional Hetero Ring Is Attached Directly Or Indirectly To The Bicyclo Ring System By Nonionic Bonding Patents (Class 514/259.41)
-
Patent number: 11648207Abstract: Disclosed is an extended release pharmaceutical composition of Clozapine, which can be provided as a reservoir type dosage form, and when dosed to a patient once daily achieves at steady state, AUC0-24h, Cmax and Cmin in patient plasma that are within 80 to 125% bioequivalence criteria compared to immediate release Clozapine dosed at the same total daily dose divided twice per day. Further, the pharmaceutical composition of Clozapine can provide once daily dosing regimen in order to improve patient compliance and reduces side effects in patients in need thereof. The pharmaceutical composition further lacks any significant food effect on oral administration.Type: GrantFiled: April 8, 2022Date of Patent: May 16, 2023Inventors: Rikin Patel, Kavan Pandya, Piyush Kansagra, Satyavan Dhavale, Ashish Sehgal
-
Patent number: 11180495Abstract: This application describes a nitrogen heteroaryl derivative having CSF1R inhibitory activity, and a preparation method therefor and an application thereof. Compounds in the present invention has a structure represented by formula (I) as below, and the definition on substituents is as stated in the description and the claims. The compounds in the this application can be widely applied to preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease, or metastatic disease, in particular ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, metastasis of primary tumor sites, or osseous metastatic cancer, and a new generation of CSF1R inhibitor drugs is expected to be developed.Type: GrantFiled: June 13, 2018Date of Patent: November 23, 2021Assignee: ABBISKO THERAPEUTICS CO., LTD.Inventors: Mingming Zhang, Baowei Zhao, Hongping Yu, Zhui Chen, Yaochang Xu
-
Patent number: 10851101Abstract: Provided herein are compounds of Formula (I): and forms thereof, including compositions thereof and uses therewith for treating spinal muscular atrophy.Type: GrantFiled: August 15, 2019Date of Patent: December 1, 2020Assignees: PTC Therapeutics, Inc., F. Hoffman-La Roche AGInventors: Hongyan Qi, Soongyu Choi, Amal Dakka, Gary Mitchell Karp, Jana Narasimhan, Nikolai Naryshkin, Anthony A. Turpoff, Marla L. Weetall, Ellen Welch, Matthew G. Woll, Tianle Yang, Nanjing Zhang, Xiaoyan Zhang, Xin Zhao, Luke Green, Emmanuel Pinard, Hasane Ratni
-
Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
Patent number: 10478436Abstract: Methods for treating Down syndrome and improving cognitive function of a patient with an intellectual disability are disclosed. 5-hydroxytryptamine sub-receptor six (5-HT6) receptor antagonists are provided for improving the cognition of a Down syndrome patient.Type: GrantFiled: April 8, 2015Date of Patent: November 19, 2019Assignee: THE UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Julie Ruth Korenberg, Karen Sue Wilcox, Peter Jeffrey West, Raymond Pierre Kesner -
Patent number: 10280165Abstract: The invention relates to pyridopyrimidinone compounds of formula I or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5 and R6 are as defined herein, as well as pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.Type: GrantFiled: October 13, 2017Date of Patent: May 7, 2019Assignee: Genentech, Inc.Inventors: Matthew Volgraf, Yu Jiang, Elisia Villemure, Benjamin Sellers, Guosheng Wu, Aijun Lu
-
Patent number: 9963449Abstract: The present invention relates to a process for the preparation of pure Paliperidone Palmitate, which comprises: (a) providing a solution of Paliperidone Palmitate in an alcoholic solvent; (b) adding the alcoholic solution of Paliperidone palmitate to water or vice versa; and (c) isolating the product to obtain pure Paliperidone Palmitate.Type: GrantFiled: January 13, 2016Date of Patent: May 8, 2018Assignee: Aurobindo Pharma LtdInventors: Sandeep Jain, Srikanth Sindhanur, Anil Kumar Jain, Sivakumaran Meenakshisunderam
-
Patent number: 9751953Abstract: Disclosed is an antibody which binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of risperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.Type: GrantFiled: August 20, 2013Date of Patent: September 5, 2017Assignee: JANSSEN PHARMACEUTICA NVInventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Maarten Vliegen, Pieter Rik Haspeslagh
-
Patent number: 9649304Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.Type: GrantFiled: January 19, 2010Date of Patent: May 16, 2017Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventor: Guochuan Emil Tsai
-
Patent number: 9320707Abstract: The present invention is concerned with a pharmaceutical composition suitable as a depot formulation for administration via intramuscular or subcutaneous injection, comprising: (1) as an active ingredient a therapeutically effective amount of a 9-hydroxyrisperidone fatty acid ester or a salt, or a stereoisomer or a stereoisomeric mixture thereof in submicron form and (2) a pharmaceutically acceptable carrier; wherein the pharmaceutically acceptable carrier is water and the active ingredient is suspended therein: and with a process of preparing such a composition. The invention further concerns such a pharmaceutical composition for use as a medicament in the treatment of psychosis, schizophrenia, schizoaffective disorders, non-schizophrenic psychoses, behavioral disturbances associated with neurodegenerative disorders, e.g. in dementia, behavioral disturbances in mental retardation and autism, Tourette's syndrome, bipolar mania, depression, anxiety.Type: GrantFiled: June 29, 2012Date of Patent: April 26, 2016Assignee: Janssen Pharmaceutica, N.V.Inventors: Marc Karel Jozef François, Willy Maria Albert Carlo Dries, Esther Dina Guido Basstanie
-
Patent number: 9072743Abstract: The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.Type: GrantFiled: September 26, 2013Date of Patent: July 7, 2015Assignee: Tangent Reprofilling LimitedInventors: Suzanne Dilly, Gregory Stoloff, Paul Taylor
-
Publication number: 20150147398Abstract: An injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is paliperidone and/or its pharmaceutical acceptable salts in any combination thereof, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and DMSO as solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 8 weeks and wherein the composition has a pharmacokinetic profile in vivo suitable for the formulation to be administered each 8 weeks or even longer periods.Type: ApplicationFiled: November 26, 2014Publication date: May 28, 2015Applicant: Laboratorios Farmacéuticos Rovi, S.A.Inventors: Ibon GUTIERRO ADURIZ, Guillermo FRANCO RODRÍGUEZ
-
Patent number: 9040695Abstract: The present invention relates to a novel acid addition salt of risperidone, wherein acid counterion is selected from the group consisting of pamoic acid, caproic acid, cypionic acid, decanoic acid, camphor sulfonic acid, enanthic acid, palmitic acid, fusidic acid, gluceptic acid, gluconic acid, lactobionic acid, lauric acid, levulinic acid and valeric acid, a process for the preparation and pharmaceutical composition comprising the same. Further, the invention relates to the use of said pharmaceutical composition comprising the acid addition salt of risperidone in the treatment of patient suffering from psychotic disorders.Type: GrantFiled: April 25, 2012Date of Patent: May 26, 2015Assignee: TORRENT PHARMACEUTICALS LIMITEDInventors: Sunil Sadanand Nadkarni, Arunkumar Gupta, Manish Parikh, Jaya Abraham, Vivek Mishra
-
Publication number: 20150141380Abstract: A method of treating a subject at risk of or suspected of having Fragile X syndrome or autism spectrum disorder associated with abnormalities of ERK includes administering to the subject a therapeutically effective amount of at least one ERK inhibiting compound that prevents abnormalities in neuronal connectivity, a prodrug thereof that is metabolisable to form the compound, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 5, 2011Publication date: May 21, 2015Applicant: CASE WESTERN RESERVE UNIVERSITYInventors: Mark A. Smith, Michael Snape
-
Publication number: 20150126496Abstract: The invention relates to methods for diagnosis and treatment of autism spectrum disorders, particularly for autism spectrum disorders characterized by increased head size (circumference) and deficits in social behavior.Type: ApplicationFiled: October 10, 2014Publication date: May 7, 2015Applicant: Massachusetts Institute of TechnologyInventors: Damon Theron Page, Mriganka Sur
-
Publication number: 20150119383Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.Type: ApplicationFiled: June 5, 2014Publication date: April 30, 2015Inventors: Barry S. Fogel, William D. Kerns, Kei-Lai Fong, San-Laung Chow, Edward Lin, David Wong
-
Patent number: 9017735Abstract: Disclosed herein are compositions and methods for treating a psychiatric disorder or symptoms thereof in a patient. The compositions comprise a compound that modulates KCNQ (Kv7) potassium channel activity and the methods include administering an effective amount of the compound that modulates KCNQ (Kv7) potassium channel activity.Type: GrantFiled: June 3, 2010Date of Patent: April 28, 2015Assignee: Marquette UniversityInventor: Mohammadhossein Behnam Ghasemzadeh
-
Publication number: 20150111834Abstract: The disclosure provides a recipe for in-situ gel, formed by dissolving at least one polymer and at least one gel prevention agent in a polar solvent to form a solution and placing the solution in a condition for in-situ forming gels. The disclosure also provides an implant and a drug delivery system formed by the recipe.Type: ApplicationFiled: September 17, 2014Publication date: April 23, 2015Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Felice CHENG, Maggie J.M. LU, Yi-Ju KO, Min-Ying LIN, Shuen-Hsiang CHOU
-
Patent number: 9011912Abstract: Oral dosage forms for poorly soluble amine drugs are provided. Such dosage forms include an ionizable compound such as an organic acid, an amphiphilic polymer and a release rate-controlling membrane. Such dosage forms allow for the consistent release of the active agent in both gastric pH conditions and in the intestine. Methods of making such dosage forms are also provided.Type: GrantFiled: October 7, 2010Date of Patent: April 21, 2015Assignee: Abon Pharmaceuticals, LLCInventors: Yanming Zu, Sudhir Gorukanti, Salah Uddin Ahmed
-
Patent number: 9006431Abstract: There is provided a hemihydrate form of the sodium salt of pemirolast.Type: GrantFiled: May 12, 2014Date of Patent: April 14, 2015Assignee: RSPR Pharma ABInventors: Anett Perlberg, Martin Viertelhaus, Ulrika Rosenström, Karol Horvath
-
Publication number: 20150099015Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.Type: ApplicationFiled: November 24, 2014Publication date: April 9, 2015Inventor: Guochuan Emil TSAI
-
Publication number: 20150099767Abstract: The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite, or a prodrug thereof.Type: ApplicationFiled: September 18, 2014Publication date: April 9, 2015Inventor: Eric Dadey
-
Publication number: 20150080372Abstract: Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on each of B-Raf, B-Raf V600E and c-Raf-1 protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line.Type: ApplicationFiled: October 14, 2014Publication date: March 19, 2015Inventors: Prabha N. Ibrahim, Guoxian Wu, Jack Lin, Wayne Spevak, Hanna Cho, Todd Ewing, Chao Zhang
-
Patent number: 8980900Abstract: The present invention provides the use of certain compounds to treat peripheral or central pain syndrome and other disorders associated with the T-type calcium ion channels.Type: GrantFiled: September 9, 2014Date of Patent: March 17, 2015Assignee: VM Therapeutics, LLC.Inventor: Jay Jie-Qiang Wu
-
Publication number: 20150064118Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.Type: ApplicationFiled: September 15, 2014Publication date: March 5, 2015Inventors: Krister THURESSON, Fredrik TIBERG, Markus JOHANSSON, Ian HARWIGSSON, Fredrik JOABSSON, Markus JOHNSSON
-
Patent number: 8940749Abstract: An improved process for the synthesis of 3-[2-[4-((6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one (Paliperidone) and Paliperidone Palmitate through a novel intermediate (2-Chloroethyl)-6,7,8,9-tetrahydro-2-methyl-9-hydroxy-4H-pyrido [1,2-a]pyrimidine-4-one Palmitate ester.Type: GrantFiled: May 30, 2012Date of Patent: January 27, 2015Inventors: Ramamohan Rao Davuluri, Ravi Ponnaiah, Praveen Kumar Neela, Guruswamy Batthini, Telagareddy Venkata Narasimharao, Kosireddy Ravanababu, Kallepally Sudheer
-
Publication number: 20150005323Abstract: The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite, or a prodrug thereof.Type: ApplicationFiled: September 18, 2014Publication date: January 1, 2015Inventor: Eric Dadey
-
Patent number: 8920835Abstract: A paliperidone double-layered osmotic pump controlled release tablet and the preparation method thereof are disclosed. The double-layered osmotic pump controlled release tablet comprises a rigid membrane, a push layer, a drug layer, an isolation layer and an aesthetic coating, wherein the rigid membrane contains a semi-permeable polymer, a porogen and/or a plasticizer and has one or more drug release orifices on one end, the push layer comprises an expanding material, an osmotic agent, a binder, a colorant and a lubricant, the drug layer contains a pharmaceutically active ingredient, a hydrophilic polymer, an osmotic agent, a colorant, a lubricant and an antistatic agent, the isolation layer is located between the inner surface of the rigid membrane and the push layer, and contains a hydrophilic polymer. The paliperidone double-layered osmotic pump controlled release tablet shows an increasing drug release rate at early stage and keeps a constant drug release rate at later stage.Type: GrantFiled: November 22, 2010Date of Patent: December 30, 2014Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, QILU Pharamceutical Co., Ltd.Inventors: Yong Gan, Chunliu Zhu, Qingmin Yang, Jingyi Wang, Xiaoqing Zheng, Li Gan, Xinxin Zhang
-
Publication number: 20140378476Abstract: The present invention provides the use of certain compounds to treat peripheral or central pain syndrome and other disorders associated with the T-type calcium ion channels.Type: ApplicationFiled: September 9, 2014Publication date: December 25, 2014Inventor: Jay Jie-Qiang Wu
-
Publication number: 20140378475Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: ApplicationFiled: June 25, 2014Publication date: December 25, 2014Inventors: Douglas G. Batt, Myra Beaudoin Bertrand, George Delucca, Michael A. Galella, Soo Sung Ko, Charles M. Langevine, Qingjie Liu, Qing Shi, Anurag S. Srivastava, Joseph A. Tino, Scott Hunter Watterson
-
Publication number: 20140356292Abstract: A method of evaluating memory/learning functions with the use of a model with glutamic acid N-methyl-D-aspartate (NMDA) type receptor hypofunction as an animal model for schizophrenia and with the use of reference memory task, wherein there has been found concrete means for detecting any differences in activity between typical anti-psychosis drugs and atypical anti-psychosis drugs is found. An in vivo animal model for screening of a therapeutic agent for improving cognitive dysfunction by schizophrenia is provided.Type: ApplicationFiled: August 14, 2014Publication date: December 4, 2014Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventor: Takeo ISHIYAMA
-
Publication number: 20140350000Abstract: This document provides methods and materials related to genetic markers for predicting response to a treatment for schizophrenia (SZ). For example, methods for using such genetic markers to select optimal treatments are provided.Type: ApplicationFiled: August 13, 2014Publication date: November 27, 2014Inventors: Mark David Brennan, Timothy Lynn Ramsey
-
Publication number: 20140349999Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.Type: ApplicationFiled: June 5, 2014Publication date: November 27, 2014Inventors: Daniel Deaver, Mark Todtenkopf
-
Publication number: 20140343080Abstract: The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.Type: ApplicationFiled: May 23, 2014Publication date: November 20, 2014Applicant: The Trustees of the University of PennsylvaniaInventors: Steven SIEGEL, Karen Winey
-
Publication number: 20140329839Abstract: There is provided a hemihydrate form of the sodium salt of pemirolast.Type: ApplicationFiled: May 12, 2014Publication date: November 6, 2014Applicant: CARDOZ ABInventors: Anett Perlberg, Martin Viertelhaus, Ulrika Rosenström, Karol Horvath
-
Publication number: 20140315892Abstract: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing an alcohol-related or addictive disorder. The (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.Type: ApplicationFiled: January 31, 2014Publication date: October 23, 2014Inventors: Anthony Alexander McKinney, Franklin Porter Bymaster
-
Patent number: 8865727Abstract: The present invention provides the use of certain compounds to treat peripheral or central pain syndrome and other disorders associated with the T-type calcium ion channels.Type: GrantFiled: August 27, 2010Date of Patent: October 21, 2014Assignee: VM Therapeutics LLCInventor: Jay Jie-Qiang Wu
-
Publication number: 20140309181Abstract: Small compounds that modulate the expression of and/or function of sodium channel, voltage-gated, alpha subunit (SCNxA) are presented. Pharmaceutical compositions containing such small molecules and their use in treating diseases and disorders associated with the expression of SCNxA are also presented.Type: ApplicationFiled: August 28, 2012Publication date: October 16, 2014Applicant: CuRNA, Inc.Inventors: Joseph Collard, Olga Khorkova Sherman, Jane H. Hsiao
-
Publication number: 20140308352Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed.Type: ApplicationFiled: March 11, 2014Publication date: October 16, 2014Applicants: ZOGENIX INC., DURECT CORPORATIONInventors: Jeremy C. WRIGHT, Wilma TAMRAZ, John J. LEONARD, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK, Brooks BOYD, Christopher M. RUBINO
-
Patent number: 8859563Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compound of Formula I is also provided.Type: GrantFiled: February 27, 2012Date of Patent: October 14, 2014Assignee: Avexa LimitedInventors: Eric Dale Jones, Jonathan Alan Victor Coates, David Ian Rhodes, John Joseph Deadman, Nicholas Andrew Van de Graff, Lisa Jane Winfield, Neeranat Thienthong, William Issa, Neil Choi, Katherine Macfarlane
-
Publication number: 20140303189Abstract: The invention provides a patch containing a support and, formed thereon, an adhesive layer retaining a drug. The adhesive layer contains a thermoplastic elastomer, a liquid component in an amount exceeding 300 parts by weight relative to 100 parts by weight of the elastomer, and risperidone or a salt thereof, and optionally a tackifier of not more than 10 wt %.Type: ApplicationFiled: August 17, 2012Publication date: October 9, 2014Applicant: KM TRANSDERM LTD.Inventors: Masaoki Goto, Atsuyo Hamada, Mitsuji Akazawa, Keiko Yamasaki, Shoji Miyaji
-
Publication number: 20140296257Abstract: The present invention relates to water-soluble carrier-linked prodrugs of formula (I), wherein B, A and Hyp form the carrier, B is a branching core, each A is independently a poly(ethylene glycol)-based polymeric chain, each Hyp is independently a branched moiety, each SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, each D is independently a biologically active moiety, each x is independently 0 or 1, each m is independently an integer of from 2 to 64, n is an integer from 3 to 32; or the pharmaceutically acceptable salt thereof. It further relates to pharmaceutical compositions comprising said water-soluble carrier-linked prodrugs, their use as medicament or diagnostic, and methods of treatment.Type: ApplicationFiled: August 10, 2012Publication date: October 2, 2014Applicant: Ascendis Pharma A/SInventors: Ulrich Hersel, Guillaume Maitro, Harald Rau, Dirk Vetter
-
Publication number: 20140296140Abstract: An equipment assembly for preparing, harvesting and collecting particles is disclosed. The assembly comprises a tandem filter system with one or more high pressure filters, one or more low pressure filters and one or more collection vessel. Particles can be prepared, harvested and collected continuously, semi-continuously or in a batch-type operation. A tandem filter system and its method of use are also disclosed. Particles made with the assembly and according the instant methods are also disclosed. The assembly provides improved particle harvesting and collection over other systems and permits continuous particle formation, in particular by dispersion of a solute-containing process fluid within a supercritical anti-solvent.Type: ApplicationFiled: June 17, 2014Publication date: October 2, 2014Applicant: CRITITECH, INC.Inventors: Greg S. JOHNSON, Bala SUBRAMANIAM, Fenghui Niu
-
Publication number: 20140288054Abstract: This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ), and methods of use thereof.Type: ApplicationFiled: October 29, 2013Publication date: September 25, 2014Applicant: SureGene, LLCInventors: Mark David Brennan, Timothy Lynn Ramsey
-
Publication number: 20140255517Abstract: In certain embodiments, the disclosure relates to methods of treating or preventing posttraumatic stress disorder comprising administering a pharmaceutical composition comprising effective amount of an angiotensin-converting enzyme inhibitor to a subject in need thereof. In certain embodiments, the angiotensin-converting enzyme inhibitor is administered in combination with an angiotensin receptor blocker.Type: ApplicationFiled: March 5, 2014Publication date: September 11, 2014Applicant: EMORY UNIVERSITYInventors: Kerry J. Ressler, Paul J. Marvar
-
Publication number: 20140248378Abstract: The present invention provides compounds of formula (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, Y and Z are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: ApplicationFiled: July 5, 2012Publication date: September 4, 2014Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Xiao-Ling Fan Cockcroft, William Farnaby, Natasha Kinsella, Kevin Merchant, David Miller
-
Publication number: 20140242088Abstract: A pharmaceutical combination comprising an Hsp90 inhibitor and an mTOR inhibitor, and methods of using the combination to treat or prevent proliferative disorders.Type: ApplicationFiled: April 30, 2014Publication date: August 28, 2014Applicant: Novartis AGInventors: Carlos Garcia-Echeverria, Michael Rugaard Jensen
-
Publication number: 20140242063Abstract: The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder.Type: ApplicationFiled: October 10, 2013Publication date: August 28, 2014Applicant: VALEANT LABORATORIES INTERNATIONAL BERMUDAInventors: Andrew John DUFFIELD, Graham JACKSON, Steven E. FRISBEE
-
Publication number: 20140234443Abstract: Novel 5-HT3 receptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, and irritable bowel syndrome. Methods of making these compounds are also described in the present invention.Type: ApplicationFiled: March 10, 2014Publication date: August 21, 2014Applicant: Albany Molecular Research, Inc.Inventors: Peter R. GUZZO, David D. MANNING, William EARLEY
-
Patent number: 8808746Abstract: Provided, among other things, are compositions and methods for making sustained-release microspheres, as well as a microsphere delivery system for the sustained release of an active agent. The microsphere delivery system comprises a homogeneous mixture of biodegradable polymer, active agent, and a so-called release-modifying agent (including a pH-stabilizing agent), and provides protected and sustained release of active agents from the microsphere delivery system. According to the invention, the microspheres preferably are produced by an oil-in-water emulsion method that involves the production of a homogeneous oil phase prepared by mixing active agent and a release-modifying agent, such as arginine, with biodegradable polymer, each dissolved in organic solvent.Type: GrantFiled: April 29, 2005Date of Patent: August 19, 2014Assignee: Fresenius Kabi USA, LLCInventors: Byung Ho Woo, Sumeet H. Dagar, Kang Yong Yang
-
Publication number: 20140206667Abstract: The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an antipsychotic or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In some embodiments, the methods and the compositions are for treating one or more positive and/or negative symptoms, as well as cognitive impairment, associated with schizophrenia or bipolar disorder (in particular, mania).Type: ApplicationFiled: November 14, 2013Publication date: July 24, 2014Inventor: Michela Gallagher